Equasens Société anonyme Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Equasens Société anonyme wird ein jährliches Gewinn- und Umsatzwachstum von 7.3% bzw. 5.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.6% betragen.
Wichtige Informationen
6.6%
Wachstumsrate der Gewinne
6.4%
EPS-Wachstumsrate
| Healthcare Services Gewinnwachstum | 25.8% |
| Wachstumsrate der Einnahmen | 5.1% |
| Zukünftige Eigenkapitalrendite | 17.9% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 05 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Sep 28
Equasens Société anonyme's (EPA:EQS) Intrinsic Value Is Potentially 75% Above Its Share Price
Jul 15Equasens Société anonyme's (EPA:EQS) Upcoming Dividend Will Be Larger Than Last Year's
Jun 22Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Jun 07Equasens Société anonyme (EPA:EQS) Is Aiming To Keep Up Its Impressive Returns
Apr 03At €51.10, Is It Time To Put Equasens Société anonyme (EPA:EQS) On Your Watch List?
Mar 08Some Confidence Is Lacking In Equasens Société anonyme's (EPA:EQS) P/E
Feb 14Estimating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 27Should You Investigate Equasens Société anonyme (EPA:EQS) At €59.70?
Nov 29These 4 Measures Indicate That Equasens Société anonyme (EPA:EQS) Is Using Debt Safely
Oct 28A Look At The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Sep 27Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Aug 05Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.15
Jun 11Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 22Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 08What Does Equasens Société anonyme's (EPA:EQS) Share Price Indicate?
Apr 04Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends
Feb 13Calculating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 26At €71.60, Is Equasens Société anonyme (EPA:EQS) Worth Looking At Closely?
Dec 21Should You Be Adding Equasens Société anonyme (EPA:EQS) To Your Watchlist Today?
Dec 07Here's What's Concerning About Equasens Société anonyme's (EPA:EQS) Returns On Capital
Nov 12Is Equasens Société anonyme (EPA:EQS) Trading At A 26% Discount?
Oct 27Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Oct 12When Should You Buy Equasens Société anonyme (EPA:EQS)?
Sep 09With EPS Growth And More, Equasens Société anonyme (EPA:EQS) Makes An Interesting Case
Aug 24Equasens Société anonyme (EPA:EQS) Might Be Having Difficulty Using Its Capital Effectively
Jul 28Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.05
Jun 10Pharmagest Interactive (EPA:PHA) Has Announced That It Will Be Increasing Its Dividend To €1.05
May 27Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
May 22Here's What Pharmagest Interactive's (EPA:PHA) Strong Returns On Capital Mean
Apr 25Are Investors Undervaluing Pharmagest Interactive SA (EPA:PHA) By 28%?
Feb 23Here's Why I Think Pharmagest Interactive (EPA:PHA) Might Deserve Your Attention Today
Feb 09Is Pharmagest Interactive SA (EPA:PHA) Potentially Undervalued?
Jan 25Many Would Be Envious Of Pharmagest Interactive's (EPA:PHA) Excellent Returns On Capital
Jan 06Pharmagest Interactive (EPA:PHA) Could Easily Take On More Debt
Nov 14Is There An Opportunity With Pharmagest Interactive SA's (EPA:PHA) 20% Undervaluation?
Oct 30Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
Sep 28Is Pharmagest Interactive SA (EPA:PHA) Trading At A 20% Discount?
Jul 18Pharmagest Interactive (EPA:PHA) Will Want To Turn Around Its Return Trends
Jun 24Does Pharmagest Interactive (EPA:PHA) Deserve A Spot On Your Watchlist?
Apr 08Pharmagest Interactive SA (EPA:PHA) Is An Attractive Dividend Stock - Here's Why
Mar 24Pharmagest Interactive SA's (EPA:PHA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 03Our Take On The Returns On Capital At Pharmagest Interactive (EPA:PHA)
Feb 09
Shareholders of Pharmagest Interactive (EPA:PHA) Must Be Delighted With Their 500% Total Return
Jan 12What To Know Before Buying Pharmagest Interactive SA (EPA:PHA) For Its Dividend
Dec 15Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmagest Interactive SA's EPA:PHA) Stock?
Dec 01Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 254 | 56 | 58 | 71 | 4 |
| 12/31/2025 | 241 | 51 | 53 | 67 | 4 |
| 12/31/2024 | 223 | 45 | 50 | 63 | 4 |
| 12/31/2023 | 220 | 47 | 39 | 58 | N/A |
| 6/30/2023 | 223 | 48 | 59 | 71 | N/A |
| 3/31/2023 | 219 | 47 | 53 | 64 | N/A |
| 12/31/2022 | 214 | 46 | 47 | 57 | N/A |
| 6/30/2022 | 203 | 42 | 42 | 51 | N/A |
| 3/31/2022 | 198 | 41 | 40 | 49 | N/A |
| 12/31/2021 | 193 | 39 | 37 | 48 | N/A |
| 9/30/2021 | 190 | 37 | 38 | 51 | N/A |
| 6/30/2021 | 188 | 35 | 39 | 54 | N/A |
| 3/31/2021 | 180 | 33 | 33 | 51 | N/A |
| 12/31/2020 | 172 | 31 | 28 | 47 | N/A |
| 9/30/2020 | 166 | 29 | 22 | 41 | N/A |
| 6/30/2020 | 160 | 27 | 17 | 35 | N/A |
| 3/31/2020 | 159 | 27 | 20 | 38 | N/A |
| 12/31/2019 | 159 | 27 | 24 | 41 | N/A |
| 9/30/2019 | 156 | 27 | 23 | 38 | N/A |
| 6/30/2019 | 153 | 26 | 21 | 36 | N/A |
| 3/31/2019 | 151 | 26 | 20 | 33 | N/A |
| 12/31/2018 | 148 | 25 | 18 | 29 | N/A |
| 9/30/2018 | 144 | 25 | 21 | 31 | N/A |
| 6/30/2018 | 139 | 24 | 24 | 33 | N/A |
| 3/31/2018 | 134 | 24 | 22 | 30 | N/A |
| 12/31/2017 | 130 | 23 | 19 | 27 | N/A |
| 9/30/2017 | 129 | 22 | N/A | 26 | N/A |
| 6/30/2017 | 128 | 21 | N/A | 26 | N/A |
| 3/31/2017 | 128 | 21 | N/A | 24 | N/A |
| 12/31/2016 | 128 | 21 | N/A | 23 | N/A |
| 9/30/2016 | 125 | 20 | N/A | 22 | N/A |
| 6/30/2016 | 121 | 20 | N/A | 22 | N/A |
| 3/31/2016 | 117 | 19 | N/A | 21 | N/A |
| 12/31/2015 | 113 | 19 | N/A | 20 | N/A |
| 9/30/2015 | 113 | 18 | N/A | 20 | N/A |
| 6/30/2015 | 112 | 18 | N/A | 21 | N/A |
| 3/31/2015 | 113 | 17 | N/A | 19 | N/A |
| 12/31/2014 | 115 | 17 | N/A | 17 | N/A |
| 9/30/2014 | 114 | 17 | N/A | 19 | N/A |
| 6/30/2014 | 113 | 16 | N/A | 21 | N/A |
| 3/31/2014 | 113 | 16 | N/A | 17 | N/A |
| 12/31/2013 | 113 | 16 | N/A | 12 | N/A |
| 9/30/2013 | 113 | 15 | N/A | 11 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EQSDas prognostizierte Gewinnwachstum (7.3% pro Jahr) liegt über der Sparquote (1.1%).
Ertrag vs. Markt: EQSDie Erträge des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (11% pro Jahr).
Hohe Wachstumserträge: EQSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: EQSDie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.8% pro Jahr).
Hohe Wachstumseinnahmen: EQSDie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EQSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.6%).